FIELD: medicine.
SUBSTANCE: there is described anti-HIV monoclonal antibody that identifies a peptide with a sequence SEQ ID NO 7, or analogue thereof where the region specifying complementarity 3 (CDR3) of variable region of H-(heavy) chain, contains SEQ ID NO 1, or functional analogue thereof. There is described variable region of H-chain specifying SEQ ID NO 7, or its analogue where CDR 3 contains SEQ ID NO 1, or functional analogue thereof. There is presented nucleic acid molecule coding the described antibody. There is offered expression vector containing specified nucleic acid. There is offered host-cell transformed by specified nucleic acid molecule or offered vector. There is disclosed anti-HIV pharmaceutical composition containing the effective amount of described antibody or specified nucleic acid molecule, offered vector or host-cell. There is offered method for passive immunotherapy of an individual susceptible to HIV infection that involves introduction to said individual of described antibody or functional fragment thereof in therapeutically effective amount. There is also offered method for detection in vitro of HIV strains in a sample that involves the stage of bringing the sample in contact to described antibody or functional fragment thereof.
EFFECT: invention allows neutralising HIV infection, reducing infection through mucous membranes and performing passive immunotherapy.
18 cl, 8 dwg, 1 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODY OR FRAGMENT THEREOF, HAVING NEUTRALISING EFFECT ON HIV, BUT NOT ON IL2 | 2005 |
|
RU2393873C2 |
ANTIBODIES SPECIFIC TO BTN2 AND THEIR APPLICATIONS | 2018 |
|
RU2794996C2 |
ALLOSTERIC ANTIBODIES AGAINST HUMAN HER3 NON COMPETITIVE FOR NEUREGULIN AND USE THEREOF | 2013 |
|
RU2704228C2 |
gp41-NEUTRALIZING ANTIBODIES AND THEIR APPLICATION | 2012 |
|
RU2624046C2 |
ANTIBODIES AGAINST A5 REPRESENTATIVE OF 19 FAMILY WITH SIMILARITY OF SEQUENCES AND THEIR APPLICATION METHOD | 2019 |
|
RU2785436C2 |
BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
RECOMBINANT ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), OBTAINED BY VARIABLE REGION MUTAGENESIS | 2011 |
|
RU2557309C2 |
Aβ-PEPTIDE ANTIBODIES AND APPLICATION THEREOF | 2003 |
|
RU2341533C2 |
MOLECULES WHICH BIND TO 4-1BB | 2011 |
|
RU2710717C2 |
ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
Authors
Dates
2010-01-27—Published
2005-05-02—Filed